Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-CDK: Olaparib + Fulvestrant in HR+ Breast Cancer
NCT05536128Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in breast cancer, sponsored by Seoul National University Hospital. Started Dec 2022; status: recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05536128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05536128.